Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Alzheimer's Medication Trials

New Jersey

Alzheimer's medication trials in New Jersey

20 Alzheimer's medication studies are recruiting participants at sites in 8 cities across New Jersey as of November 17, 2026, according to ClinicalTrials.gov.

Call (888) 927-5916
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every New Jersey city with a recruiting study

Toms River (9), Springfield (4), Marlton (3), New Brunswick (2), West Long Branch (2), Englewood (1), Princeton (1), Ridgewood (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Recently updated studies in New Jersey

Basic details from each study's public record (the 12 most recently updated of 20). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

    • Phase 3
    • Ages 60 to 85
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    Springfield · West Long Branch
    Registry record
    NCT06976203 · updated
  2. A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

    • Phase 3
    • Ages 60 to 85
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    Toms River
    Registry record
    NCT06976216 · updated
  3. A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

    • Phase 2
    • Ages 55 to 90
    • All sexes
    Sponsor
    MapLight Therapeutics
    Recruiting in
    West Long Branch
    Registry record
    NCT06887192 · updated
  4. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    Princeton
    Registry record
    NCT07011732 · updated
  5. A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

    • Phase 2
    • Ages 55 to 85
    • All sexes
    Sponsor
    Sanofi
    Recruiting in
    Springfield
    Registry record
    NCT07688213 · updated
  6. ACP-204 in Adults With Alzheimer's Disease Psychosis

    • Phase 2/3
    • Ages 55 to 95
    • All sexes
    Sponsor
    ACADIA Pharmaceuticals Inc.
    Recruiting in
    Marlton
    Registry record
    NCT06159673 · updated
  7. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

    • Phase 2
    • Ages 55 and older
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Recruiting in
    Toms River
    Registry record
    NCT06540833 · updated
  8. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

    • Phase 2
    • Ages 55 and older
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Recruiting in
    Toms River
    Registry record
    NCT06651567 · updated
  9. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    Toms River
    Registry record
    NCT07011745 · updated
  10. A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

    • Phase 1
    • Ages 50 to 85
    • All sexes
    Sponsor
    Eli Lilly and Company
    Recruiting in
    Toms River
    Registry record
    NCT06297590 · updated
  11. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

    • Phase 3
    • Ages 55 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Recruiting in
    Springfield
    Registry record
    NCT07602582 · updated
  12. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Recruiting in
    Toms River
    Registry record
    NCT06585787 · updated

Source: ClinicalTrials.gov. Data processed . See every Alzheimer's disease study recruiting in New Jersey on ClinicalTrials.gov.

Ask about studies in New Jersey

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

Alzheimer's Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5916

or send a short form

How should we reach you?

Call